Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis.
|
30903103 |
2019 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our data showed that Mst1 overexpression promoted breast cancer cell death in a manner dependent on mitochondrial apoptosis.
|
30809096 |
2019 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, expression of MST1 and MST2 was down-regulated in human breast carcinoma.
|
31212215 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We evaluated <i>ESR1</i> methylation in CTCs and paired plasma ctDNA as a potential biomarker for response to everolimus/exemestane treatment.<b>Experimental Design:</b> A highly sensitive and specific real-time MSP assay for <i>ESR1</i> methylation was developed and validated in (i) 65 primary breast tumors formalin-fixed paraffin-embedded (FFPE), (ii) EpCAM<sup>+</sup> CTC fractions (122 patients and 30 healthy donors; HD), (iii) plasma ctDNA (108 patients and 30HD), and (iv) in CTCs (CellSearch) and in paired plasma ctDNA for 58 patients with breast cancer.
|
29284708 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
HGFL-mediated RON signaling supports breast cancer stem cell phenotypes via activation of non-canonical β-catenin signaling.
|
28938607 |
2017 |
Breast Carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MSP study showed that the promoter region of ALX4 was hyper-methylated 100% (3/3) in breast cancer cell lines and 69.44% (75/108) in primary breast tumors tissues while 0% (0/8) in normal breast tissues.
|
29183346 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis.
|
28114269 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results of the present study indicated that Mst1 is a strong prognostic and predictive factor in human breast cancer and a promising anticancer target.
|
29098035 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We hypothesized that MST1/2 and LATS1/2 localization differently impacts the efficacy of neoadjuvant therapy (NAT) in breast cancer, being protective when expressed in the cytoplasm of tumor cells and in tumor-infiltrating lymphocytes, whereas representing molecular determinants of chemoresistance when present in the nucleus as a consequence of their cooperation with the DDR.
|
28387539 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Quantification of CDO1 methylation was developed using Q-MSP, and assessed in primary BC.
|
26785325 |
2016 |
Breast Carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
In our study, we carried out the MSP assay to evaluation the methylation status at CpG islands in the cyclin D2 promoter in breast cancer cases from the Vietnamese population.
|
25824739 |
2015 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The status of PRKD1 promoter methylation was analyzed by reduced representation bisulfite deep sequencing, methylation-specific PCR (MSP-PCR) and in situ MSP-PCR in invasive and noninvasive breast cancer lines, as well as in humans in 34 cases of "normal" tissue, 22 cases of ductal carcinoma in situ, 22 cases of estrogen receptor positive, HER2-negative (ER+/HER2-) invasive lobular carcinoma, 43 cases of ER+/HER2- invasive ductal carcinoma (IDC), 93 cases of HER2+ IDC and 96 cases of triple-negative IDC.
|
23971832 |
2013 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Met-DNA in serum detected with the OS-MSP assay constitutes a significant and independent prognostic factor, and its combination with total DNA in serum seems to be even more effective for prediction of prognosis for breast cancer patients.
|
22964822 |
2012 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Western analysis revealed that treatment of the T47D human breast cancer cell line with tamoxifen and HGFL was associated with increased phosphorylation of mitogen-activated protein kinase (MAPK) 1/2 and phosphorylation of serine residue 118 of ER.
|
20689759 |
2010 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Herein we investigate the regulation of Brk kinase activity and cell migration in response to treatment of keratinocytes (HaCaT cells) and breast cancer cell lines (MDA-MB-231 and T47D cells) with hepatocyte growth factor (HGF) and macrophage stimulating protein (MSP), peptide ligands for Met and Ron receptors, respectively.
|
20687930 |
2010 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have analyzed the role of recepteur d'origine nantais (RON), a tyrosine kinase receptor for macrophage-stimulating protein (MSP) that plays a role in breast cancer cell invasion as one of the molecular targets of HIF-1alpha.
|
19307182 |
2009 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data suggest that signaling initiated by MSP is an important contributor to metastasis of breast cancer and introduce an independent biomarker for assessing the prognosis of humans with breast cancer.
|
17456594 |
2007 |